 |
市場調査レポート
中国の糖尿病市場の分析：患者数、有病率、経口抗糖尿病剤、インスリン、診断薬China Diabetes Market Report: 2019-2024 |
||||||
| 発行 | IMARC Services Private Limited | 商品コード | 345918 | ||||
| 出版日 | ページ情報 | 英文 92 Pages 納期: 2-3営業日 |
|||||
| 価格 |
|
||||||
| 中国の糖尿病市場の分析：患者数、有病率、経口抗糖尿病剤、インスリン、診断薬 China Diabetes Market Report: 2019-2024 | ||
| 出版日: 2019年06月10日 | ページ情報: 英文 92 Pages |
|
中国は世界最大の糖尿病患者人口を抱えており、また近年では成人の間で発症者数が急速に増加しています。約30年前には、糖尿病患者は成人人口の1%未満でしたが、現在では約12%にまで拡大しています。その要因として、急速な経済成長や都市化、食生活の変化 (脂肪・白米の消費量増加)、認知度の低さ、貧弱な医療インフラ、座り仕事中心の生活 (運動量の低下) の他、中国人が全般的に西洋人よりも糖尿病に罹りやすい体質であることなどが挙げられます。政府や医療関係者の緊急対応が求められている一方で、こうした状況は、糖尿病の治療薬・診断薬メーカーにとっては巨大な市場機会の出現とも言えるでしょう。
当レポートでは、中国国内の糖尿病治療薬・診断薬の市場について分析し、有病者数の推移・予測や構造 (年齢・性別など)、市場への主な影響要因、治療薬・診断薬の市場規模と今後の見通し、今後の市場機会などについて調査・推計しております。
China currently has the highest number of diabetics in the world. The disease has presently reached epidemic proportions in the adult population. Around three decades ago, less than one percent of the Chinese adult population had diabetes. These levels, however, have increased to around 12 percent - making it the diabetes capital of the world.
The rise of diabetes in China can be attributed to a number of factors. Driven by a strong economic growth over the past few decades, the Chinese population has become richer, fatter and less mobile. Apart from urbanisation and sedentary lifestyles, Chinese people are also genetically more vulnerable to diabetes compared to Europeans and many other population groups. Other factors such as poor awareness of health issues, high consumption of white rice, poor healthcare infrastructure, etc. have also driven the prevalence of the disease.
China's diabetes statistics may ring alarm bells for the government and healthcare authorities, for drug and diagnostic manufacturers, however, it represents a goldmine. Fuelled by a continuous increase in healthcare expenditures, the market for diabetes drugs and diagnostics is expanding robustly in the country. This is creating lucrative opportunities for global healthcare companies at a time when growth rates in the more developed markets have declined.
According to the latest report by IMARC Group, titled "China Diabetes Market Report: 2019-2024", the China diabetes market reached a value of US$ 3.37 Billion in 2018, exhibiting a CAGR of 12.48% during 2011-2018. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in China. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Chinese diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the China diabetes market in any form.
